Ribavirin: all 452 studies that test it
Page 3 of 5. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose RibavirinCompletedNCT00491179Phase 4Results posted
- The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)CompletedNCT00483938Phase 3Results posted
- S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis CCompletedNCT00475176Phase 2Results posted
- The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)TerminatedNCT00441584Phase 3Results posted
- Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)CompletedNCT00423670Phase 2Results posted
- A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)CompletedNCT00420784Phase 2Results posted
- A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis CCompletedNCT00394277Phase 4Results posted
- Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis CCompletedNCT00372385Phase 2Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infectionCompletedNCT00353418Phase 4Results posted
- Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)CompletedNCT00302081Phase 3Results posted
- Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)TerminatedNCT00255034Phase 4Results posted
- Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)TerminatedNCT00255008Phase 4Results posted
- Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)CompletedNCT00202839Phase 4Results posted
- A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 InfectionCompletedNCT00192647Phase 4Results posted
- Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)CompletedNCT00160251Phase 2Results posted
- Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.CompletedNCT00107653Phase 4Results posted
- Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)CompletedNCT00104052Phase 3Results posted
- PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis CCompletedNCT00100659Phase 3Results posted
- REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination TherapyCompletedNCT00087646Phase 4Results posted
- PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.CompletedNCT00087633Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.CompletedNCT00087594Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + RibavirinCompletedNCT00087568Phase 4Results posted
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)CompletedNCT00081770Phase 3Results posted
- ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.CompletedNCT00077636Phase 4Results posted
- Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3CompletedNCT00056862Phase 4Results posted
- PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)CompletedNCT00039871Phase 3Results posted
- Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney DiseaseCompletedNCT00028093Phase 4Results posted
- Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected PatientsCompletedNCT00018031Phase 2Results posted
- The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue FeverCompletedNCT06744777Phase 3
- Effect of New Oral Treatment for Hepatitis C Virus on Seminal ParametersCompletedNCT05616598Phase 2/3
- Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed ConditionCompletedNCT05532306Phase 1
- Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated CirrhosisStatus unknownNCT05467826Phase 4
- MANS-NRIZ Trial for COVID-19 Treatment : Extension StudyStatus unknownNCT04959786Phase 2/3
- The Diabetes Virus Detection and Intervention TrialCompletedNCT04838145Phase 2
- Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19Status unknownNCT04828564Phase 2/3
- The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 InfectionCompletedNCT04774107Phase 1
- IFN Beta-1b and Ribavirin for Covid-19Status unknownNCT04494399Phase 2
- Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian PatientsCompletedNCT04385407Phase 2
- Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 InfectionCompletedNCT04382937Phase 3
- Treatment of Hemorrhagic Fever With RibavirinSuspendedNCT04283513Phase 2
- Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV TreatmentCompletedNCT04276688Phase 2
- A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I PatientsCompletedNCT04155515Phase 3
- A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND StudyCompletedNCT03710252Phase 4
- A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell LymphomaTerminatedNCT03585725Early Phase 1
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)CompletedNCT03537196Phase 4
- Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney DiseaseCompletedNCT03499639Phase 4
- Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis CCompletedNCT03453346Not applicable
- Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.CompletedNCT03362814Phase 2/3
- Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected PatientsCompletedNCT03250910Phase 4
- A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5AWithdrawnNCT03105349Phase 4
- Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C TreatmentCompletedNCT03090035Phase 3
- Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAVCompletedNCT03004625Phase 3
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedNCT02992457Phase 4
- Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric PatientsStatus unknownNCT02985281Phase 2/3
- Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.Status unknownNCT02950870Phase 4
- A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal ImpairmentCompletedNCT02864199Phase 4
- A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6TerminatedNCT02791256Phase 3
- Swiss HCVree TrialCompletedNCT02785666Phase 3
- Extrahepatic Insulin Resistance in Chronic Hepatitis CCompletedNCT02760355Not applicable
- Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1CompletedNCT02705534Phase 3
- Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With SofosbuvirCompletedNCT02647632Phase 2
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PCompletedNCT02634008Phase 3
- Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) CirrhoticsCompletedNCT02596880Phase 3
- A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionCompletedNCT02593162Phase 2
- Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.TerminatedNCT02558114Phase 4
- A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3WithdrawnNCT02551861Phase 2
- Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic FeverSuspendedNCT02483260Not applicable
- Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral TherapyStatus unknownNCT02469012Not applicable
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV TreatmentActive, not recruitingNCT02460133Phase 4
- Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central AfricaCompletedNCT02405013Phase 2
- Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute InfectionCompletedNCT02377856Phase 4
- A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4Status unknownNCT02371408Phase 2/3
- Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV InfectionStatus unknownNCT02261662Not applicable
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic ImpairmentCompletedNCT02259855Phase 1
- An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver TransplantCompletedNCT02165189Phase 2
- DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)CompletedNCT02156570Phase 4
- Boceprevir in End Stage Renal Disease (ESRD)WithdrawnNCT02112630Not applicable
- Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedNCT02107365Phase 2
- Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis CWithdrawnNCT02099604Phase 3
- Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C VirusCompletedNCT02098616Not applicable
- Telaprevir in Genotype 3 HCVCompletedNCT02087111Phase 4
- Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCVCompletedNCT02027493Not applicable
- Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)CompletedNCT02006745Phase 3
- Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve PatientsCompletedNCT01970904Not applicable
- Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis CCompletedNCT01903278Phase 3
- Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus InfectionStatus unknownNCT01872936Phase 2
- Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis CCompletedNCT01859962Phase 2
- A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV InfectionCompletedNCT01846832Phase 3
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedNCT01795911Phase 2
- A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CCompletedNCT01790100Phase 2
- A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)WithdrawnNCT01770223Phase 4
- A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)Status unknownNCT01731301Phase 4
- A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CCompletedNCT01726946Phase 2
- Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null RespondersCompletedNCT01725542Phase 2
- A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C VirusCompletedNCT01724086Phase 2
- A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E VirusStatus unknownNCT01698723Phase 2
- A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus TabletsCompletedNCT01697436Phase 1
- Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis cStatus unknownNCT01655966Phase 3
- Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)WithdrawnNCT01641666Phase 3
- Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis CTerminatedNCT01639547Not applicable